title: Contrast-associated nephropathy.
abstract: Contrast-associated nephropathy (CaN) has become a major cause of iatrogenic acute renal failure, especially with the increasing use of radiographic contrast media in both diagnostic and interventional procedures. CaN is the third most common cause of iatrogenic acute renal failure, and is associated with increased morbidity and in-hospital mortality. CaN typically presents as an acute rise in serum creatinine levels, usually within 48 hours after exposure to contrast media. Renal medullary ischemia secondary to contrast-induced vasoconstriction is now believed to be the most likely cause of CaN, although direct renal tubular cytotoxicity does appear to play a role. The occurrence of CaN is directly related to the number of coexisting clinical risk factors. Among the many risk factors, preexisting renal impairment, the presence of diabetes mellitus and the volume of the contrast agent administered are the most important. The most effective means of reducing the incidence of CaN is through prevention, by first identifying the risk factors and then attempting to correct for them before the administration of contrast material. Although the earliest and most well-tested preventive measure, namely intravenous hydration, continues to be the most effective way to prevent CaN, recent studies have provided many new preventive modalities. The growing use of these new agents, such as acetylcysteine, endothelin blockers, and most recently fenoldopam, has increased the options available for the prevention of CaN.
authors.affiliation: Department of Medicine, Bronx VA Medical Center, Bronx, New York, USA.
authors.forename: Vikas R
authors.initials: VR
authors.lastname: Soma
authors.forename: Erdal
authors.initials: E
authors.lastname: Cavusoglu
authors.forename: Raghuraman
authors.initials: R
authors.lastname: Vidhun
authors.forename: William H
authors.initials: WH
authors.lastname: Frishman
authors.forename: Samin K
authors.initials: SK
authors.lastname: Sharma
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003287:Contrast Media / Q000009:adverse effects*; D004232:Diuretics / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D005440:Fluid Therapy; D006801:Humans; D015994:Incidence; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D003287:Contrast Media; D004232:Diuretics; D018491:Dopamine Agonists; D065128:Endothelin Receptor Antagonists; D014665:Vasodilator Agents; D000111:Acetylcysteine